Company intelligence / Profile preview

Lena Biosciences

Atlanta, Georgia, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Lena Biosciences provides advanced in vitro platforms for preclinical drug and chemical safety testing, including models for drug-induced liver injury and mitochondrial toxicity, as well as personalized cancer drug testing. Their proprietary microphysiological systems and 3D culture platforms yield human-relevant data but are not directly involved in clinical trials for therapeutics themselves.

Therapeutic areas: GastroenterologyNeurologyMetabolic DisordersOtherOncology
Modalities: DeviceNon-pharmacological therapyMicrophysiological system3D cell culturePerfusion platformBiologic
Industry: Non-Drug Biotech

Partnerships

CELLINK (now BICO): strategic partnership for PerfusiX commercialization

Beyond the preview

Go deeper on Lena Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lena Biosciences.

Explore the full profile